Key points are not available for this paper at this time.
Despite the relatively small geographic extend of the study, the findings suggest that cross-resistance may impact the efficacy of some new IRS formulations and that alternative compounds could be prioritized in areas where neonicotinoid resistance is emerging.
Fouet et al. (Thu,) studied this question.